QEEG Clinical Report

EEGLens





The QEEG report is provided by NPCindex Company, operating under the QEEGhome brand.

Personal Data:

Name: Arash Zarei

Gender: Male

Age: 1994-04-10 - 31.7 Handedness: Right

Clinical Data:

Initial diagnosis: Drug Abuse

Medication: Paroxetine

Date of Recording: 2025-10-15 Source of Referral: Panah Clinic

This case belongs to Panah Clinic















■ EEG Quality




Z-score Information







■ TMS Reponsibility



■ EEG Neuromarker Values

Neuromarker	Region	Value	Assessment
APF - EO	Frontal	11.08	High
AFP - EC	Frontal	09.83	Normal
APF - EO	Occipital	11.38	High
AFP - EC	Occipital	09.75	Normal
Arousal Level - EO	-	-	Normal
Arousal Level - EC		-	Normal

QEEGhome Clinical Report


Panah Clinic





Denoising Information

Eye Close



Rejected Channel



Total Recording Time Remaining: 160.97 sec

Number of Eye and Muscle Elements


Eye: 2 Muscle: 1

Low Artifact Percentage

High Artifact Percentage

Total Artifact Percentage


EEG Quality: perfect



Flat Channel



Eye Open



Rejected Channel



Total Recording Time Remaining:

160.43 sec

Number of Eye and Muscle Elements

Eye: 2 Muscle: 1

Low Artifact Percentage




High Artifact Percentage



Total Artifact Percentage



EEG Quality: perfect











Pathological Assessment for Substance Abuse


Comorbid Symptoms



Relapse Index




Substance Abuse Compatibility



Functional Problems Source Detection


Eye Close








Brodmann area 18 Inferior Occipital Gyrus




Brodmann area 40 Inferior Parietal Lobule

Eye Open









Brodmann area 10 Medial Frontal Gyrus Superior Frontal Gyrus

Brodmann area 21 Middle Temporal Gyrus

Note


The Relapse graph displays the relapse index based on a combination of EEG neuromarkers. It is valid only if the patient has used each of the substances included in the chart; otherwise, the index is not applicable.


The Compatibility graph shows how closely the patient's EEG neuromarkers match typical EEG changes caused by specific substances. It helps identify the dominant substance effect in cases of multiple drug use. This index is also valid only if the patient has actually used the substances represented.





QEEG Based Predicting Medication Response





Explanation

These two tables can be considered the most important finding that can be extracted from QEEG. To prepare this list, the NPCIndex Article Review Team has studied, categorized, and extracted algorithms from many authoritative published articles on predict medication response and Pharmaco EEG studies. These articles are published between 1970 and 2021. The findings extracted from this set include 85 different factors in the raw band domains, spectrum, power, coherence, and loreta that have not been segregated to avoid complexity, and their results are shown in these diagrams. One can review details in NPCIndex.com .

Medication Recommendation

These two charts, calculate response probability to various medications, according only to QEEG indicators. Blue charts favor drug response and red charts favor drug resistance. The longer the bar, the more evidence there is in the articles. Only drugs listed in the articles are listed. These tables present the indicators reviewed in the QEEG studies and are not a substitute for physician selection.





rTMS Response Prediction

Network Performance


Accuracy: 92.10% Sensitivity: 89.13% Specificity: 97.47%

Participants Information







Features Information



Responsibility



Data Distribution




About Predicting rTMS Response

This index was obtained based on machine learning approaches and by examining the QEEG biomarkers of more than 470 cases treated with rTMS. The cases were diagnosed with depression (with and without comorbidity) and all were medication free. By examining more than 40 biomarkers capable of predicting response to rTMS treatment in previous studies and with data analysis, finally 10 biomarkers including bispectral and nonlinear features entered the machine learning process. The final chart can distinguish between RTMS responsive and resistant cases with 92.1% accuracy. This difference rate is much higher than the average response to treatment of 44%, in the selection of patients with clinical criteria, and is an important finding in the direction of personalized treatment for rTMS.





Vigilance



Vigilance Slope EC:-0.16 2min EC EC

80-120s


EEG Neuromarker Values

Neuromarker	Region	Value	Assessment
APF - EO	Frontal	11.08	High
AFP - EC	Frontal	09.83	Normal
APF - EO	Occipital	11.38	High
AFP - EC	Occipital	09.75	Normal
Alpha Asymmetry - EO	Frontal	00.03	Anxiety
Alpha Asymmetry - EC	Frontal	00.04	Anxiety
Alpha Asymmetry - EO	Occipital	00.11	Anxiety
Alpha Asymmetry - EC	Occipital	00.11	Anxiety
Beta Asymmetry - EO	Frontal	-0.06	Anxiety
Beta Asymmetry - EC	Frontal	-0.03	Anxiety
Alpha Blocking	-	-	Not Observed
Arousal Level - EO	E.	-	Normal
Arousal Level - EC	12	-	Normal
Vigilance Level - EO		06.00	Normal
Vigilance Level - EC	•	04.00	Normal
Vigilance Mean - EO	-	05.41	Normal
Vigilance Mean - EC	-	03.38	Normal
Vigilance Regulation - EO	-	-0.15	Normal
Vigilance Regulation - EC	2	-0.16	Normal
Vigilance 0 Stage (%) - E0	-	70.62	Normal
Vigilance 0 Stage (%) - EC	<u> </u>	00.00	Normal
Vigilance A1 Stage (%) - E0	w	00.00	-
Vigilance A1 Stage (%) - EC	-6	24.38	-





EEG Spectra









Z Score Summary Information


Eye Close



Eye Open




Theta/Beta Ratio








Absolute Power-Eye Close




Relative Power-Eye Close







Absolute Power-Eye Open



Relative Power-Eye Open

